Promising new treatment aims to stop devastating autoimmune attacks
NCT ID NCT05314010
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 33 times
Summary
This study tests a drug called MIL62 in 102 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves in the eyes and spinal cord. The goal is to see if MIL62 can safely prevent relapses (sudden worsening of symptoms). Participants receive the drug and are monitored for side effects and how long they stay relapse-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of Chinese PLA General Hosptial
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.